Nicorette Expands Smoking and Vaping Cessation Support
A Total Quit means achieving complete freedom from tobacco and nicotine. Although significant progress has been made in helping people stop smoking, we believe experts and public health policymakers should now broaden their focus to support both smokers and users of alternative tobacco and nicotine products in achieving a Total Quit. As the makers of Nicorette, we believe this requires two complementary approaches: ensuring people have access to effective cessation support while also addressing the growing non-therapeutic use of recreational tobacco and nicotine products through appropriate regulation.
In the U.K., we are particularly proud that Nicorette Quick Mist became the first licensed medicine for vaping cessation in 2023. By 2025, this indication had been extended across the wider Nicorette portfolio in the U.K. The brand is also contributing to public health discussions around youth nicotine dependence and the development of effective cessation policies.
Smoking continues to be one of the U.K.’s leading preventable causes of death. At the same time, the increasing popularity of vaping—particularly among young people and those who have never smoked—has created new public health challenges. Nicorette has supported the report Endgame: Managing the Disposable Vapes Ban and the Journey to a Smokefree Future, contributing to wider discussions about youth nicotine addiction and the evolution of tobacco cessation policy. These efforts reflect Kenvue’s broader commitment to helping people and communities achieve healthier outcomes.
Across Europe, we are also committed to participating in conversations about public health and nicotine use. During 2025, we engaged with the World Health Organization, the European Network for Smoking and Tobacco Prevention, and European Union policymakers to discuss youth nicotine addiction and the importance of developing public health strategies that address the rapidly changing nicotine environment.
What’s next for Nicorette in Europe?
Whether adults are seeking to stop smoking or, where officially licensed, quit vaping, Nicorette is committed to providing trusted cessation support that can help people achieve meaningful and lasting change. In line with Kenvue’s Healthy Lives Mission, the brand will continue working to improve access to cessation solutions while supporting public health initiatives throughout Europe.
Click here to know more.
In the U.K., we are particularly proud that Nicorette Quick Mist became the first licensed medicine for vaping cessation in 2023. By 2025, this indication had been extended across the wider Nicorette portfolio in the U.K. The brand is also contributing to public health discussions around youth nicotine dependence and the development of effective cessation policies.
Smoking continues to be one of the U.K.’s leading preventable causes of death. At the same time, the increasing popularity of vaping—particularly among young people and those who have never smoked—has created new public health challenges. Nicorette has supported the report Endgame: Managing the Disposable Vapes Ban and the Journey to a Smokefree Future, contributing to wider discussions about youth nicotine addiction and the evolution of tobacco cessation policy. These efforts reflect Kenvue’s broader commitment to helping people and communities achieve healthier outcomes.
Across Europe, we are also committed to participating in conversations about public health and nicotine use. During 2025, we engaged with the World Health Organization, the European Network for Smoking and Tobacco Prevention, and European Union policymakers to discuss youth nicotine addiction and the importance of developing public health strategies that address the rapidly changing nicotine environment.
What’s next for Nicorette in Europe?
Whether adults are seeking to stop smoking or, where officially licensed, quit vaping, Nicorette is committed to providing trusted cessation support that can help people achieve meaningful and lasting change. In line with Kenvue’s Healthy Lives Mission, the brand will continue working to improve access to cessation solutions while supporting public health initiatives throughout Europe.
Click here to know more.
Companies